MedTrace Logo

A Study of SB-742457, Added to Donepezil for the Treatment of Mild-to-moderate Alzheimer's Disease

NCT00710684 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 682

Last updated 2017-12-07

Study results available
· View outcomes & findings →

Summary

The study is designed to investigate the safety and efficacy of SB-742457 when added to stable donepezil treatment in subjects with mild-to-moderate Alzheimer's disease.

Conditions

Interventions

DRUG

SB-742457 15mg

SB-742457 - 15mg added to existing donepezil treatment

DRUG

SB-742457 35mg

SB-742457 - 35mg added to existing donepezil

DRUG

Placebo

Placebo added to existing donepezil

DRUG

donepezil 5-10mg

existing donepezil treatment

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-07-01
Primary Completion
2010-05-21
Completion
2010-11-16

Countries

  • United States
  • Argentina
  • Australia
  • Canada
  • Chile
  • Czechia
  • Germany
  • Italy
  • Spain

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00710684 on ClinicalTrials.gov